These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24698227)

  • 21. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
    Douwes JM; Roofthooft MT; Van Loon RL; Ploegstra MJ; Bartelds B; Hillege HL; Berger RM
    Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
    Gomberg-Maitland M; Preston IR
    Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary hypertension trials: current end points are flawed, but what are the alternatives?
    Roberts K; Preston I; Hill NS
    Chest; 2006 Oct; 130(4):934-6. PubMed ID: 17035418
    [No Abstract]   [Full Text] [Related]  

  • 26. Sildenafil for pulmonary hypertension.
    Lee AJ; Chiao TB; Tsang MP
    Ann Pharmacother; 2005 May; 39(5):869-84. PubMed ID: 15827074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combination therapy].
    Okano Y
    Nihon Rinsho; 2008 Nov; 66(11):2162-7. PubMed ID: 19051737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.
    Chin KM; Badesch DB; Robbins IM; Tapson VF; Palevsky HI; Kim NH; Kawut SM; Frost A; Benton WW; Lemarie JC; Bodin F; Rubin LJ; McLaughlin V
    Am Heart J; 2014 Feb; 167(2):218-225.e1. PubMed ID: 24439983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
    Hall SM; Davie N; Klein N; Haworth SG
    Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension.
    Levy M; Celermajer DS; Bourges-Petit E; Del Cerro MJ; Bajolle F; Bonnet D
    J Pediatr; 2011 Apr; 158(4):584-8. PubMed ID: 21035821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs.
    Papierniak ES; Lowenthal DT; Mubarak K
    Am J Ther; 2012 Jul; 19(4):300-14. PubMed ID: 21642835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Sitbon O; Delcroix M; Bergot E; Boonstra AB; Granton J; Langleben D; Subías PE; Galiè N; Pfister T; Lemarié JC; Simonneau G
    Am Heart J; 2014 Feb; 167(2):210-7. PubMed ID: 24439982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of pulmonary arterial hypertension with a focus on combination therapies.
    Benza RL; Park MH; Keogh A; Girgis RE
    J Heart Lung Transplant; 2007 May; 26(5):437-46. PubMed ID: 17449411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelin-1 across the lung circulation in patients with pulmonary arterial hypertension and influence of epoprostenol infusion.
    Selimovic N; Andersson B; Bergh CH; Sakiniene E; Carlsten H; Rundqvist B
    J Heart Lung Transplant; 2009 Aug; 28(8):808-14. PubMed ID: 19632577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.
    Farber HW; Miller DP; Meltzer LA; McGoon MD
    J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pulmonary arterial hypertension treated with prostacyclin or calcium blockers].
    Andreassen AK; Geiran O; Madsen S; Hognestad A; Simonsen S
    Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3393-6. PubMed ID: 14713978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature.
    Tam DH; Farber HW
    Am J Hematol; 2006 Jun; 81(6):443-7. PubMed ID: 16680745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
    Udeoji DU; Schwarz ER
    Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy in the management of pulmonary arterial hypertension.
    Buckley MS; Staib RL; Wicks LM
    Int J Clin Pract Suppl; 2013 May; (179):13-23. PubMed ID: 23578069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.